The team at HaemaLogiX, together with our collaborators, is researching unique immune-based treatments to improve outcomes in patients suffering from blood cancers. The goal of these treatments is to help a patient’s immune system fight their own disease. We aim to commercialise our therapies through a series of strategic partnerships. HaemaLogiX was formed as a private Australian biotech company in late 2014. Soon after, we...
The team at HaemaLogiX, together with our collaborators, is researching unique immune-based treatments to improve outcomes in patients suffering from blood cancers. The goal of these treatments is to help a patient’s immune system fight their own disease. We aim to commercialise our therapies through a series of strategic partnerships. HaemaLogiX was formed as a private Australian biotech company in late 2014. Soon after, we acquired the core proprietary technologies that are the foci of our research and development efforts to treat multiple myeloma.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.